본문 바로가기

6 '-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb-AR Pathway

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
NUTRIENTS11(9) · 2019
피인용
Web of Science 12Scopus 14
FWCI (Scopus)
0.57
JCR IF
JCR 2018 4.171
ISSN
2072-6643

저자

  1. Jin, Bo-Ram제1저자Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do, 26339, Korea
  2. Kim, Hyo-JungDepartment of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do, 26339, Korea
  3. 김은영Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Gyeongsangnam-do, 50612, Korea
  4. 정태욱Korean Medical Research Center for Healthy Aging, Pusan National University, Yangsan, Gyeongsangnam-do, 50612, Korea
  5. 하기태교신저자Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Gyeongsangnam-do, 50612, Korea
  6. An, Hyo-JinDepartment of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do, 26339, Korea

초록

Background: 6 '-Sialyllactose (6SL) displays a wide range of the bioactive benefits, such as anti-proliferative and anti-angiogenic activities. However, the therapeutic effects of 6SL on benign prostatic hyperplasia (BPH) remain unknown. Methods: Six-week-old male Wistar rats (n = 40) were used for in vivo experiments. All rats were castrated and experimental BPH was induced in castrated rats by intramuscular injection of testosterone, with the exception of those in the control group. Rats with BPH were administrated finasteride and 0.5 or 1.0 mg/kg 6SL. Furthermore, the inhibitory effects of 6SL on human epithelial BPH cell line (BPH-1) cells were determined in vitro. Results: Rats with BPH exhibited outstanding BPH manifestations, including prostate enlargement, histological alterations, and increased prostate-specific antigen (PSA) levels. Compared to those in the BPH group, rats in the 6SL group showed fewer pathological changes and normal androgen events, followed by restoration of retinoblastoma protein (pRb) and cell cycle-related proteins. In BPH-1 cells, treatment with 6SL significantly suppressed the effects on the androgen receptor (AR), PSA, and E2F transcription factor 1 (E2F1)-dependent cell cycle protein expression. Conclusions: 6SL demonstrated anti-proliferative effects in a testosterone-induced BPH rat model and on BPH-1 cells by regulating the pRB/E2F1-AR pathway. According to our results, we suggest that 6SL may be considered a potential agent for the treatment of BPH.

키워드

benign prostatic hyperplasia (BPH)6 '-Sialyllactose (6SL)pRBandrogen receptor (AR)BPH-1testosterone-induced BPH rat modelANDROGEN RECEPTORRETINOBLASTOMA PROTEINTRANSCRIPTIONOLIGOSACCHARIDESFINASTERIDECANCER

식별자

Scopus EID
2-s2.0-85072571994
WoS UID
000487964600054